Use of radiolabeled antibodies in the treatment of childhood acute leukemia

Eneida R. Nemecek, Dana C. Matthews

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Despite advances in therapy for acute leukemia, relapse continues to be the major cause of treatment failure. Hematopoietic stem cell transplant can rescue some patients after relapse, but the ability to escalate the intensity of preparative regimens is limited by toxicity to normal organs. Radiolabeled monoclonal antibodies against hematopoietic antigens have emerged as an alternative to deliver targeted supplemental radiation to sites of leukemic involvement while relatively sparing normal organs. This paper will review the rationale for using this approach, our current experience with radiolabeled anti-CD45 antibody, and the potential challenges encountered in treating children with radiolabeled antibodies.

Original languageEnglish (US)
Pages (from-to)89-94
Number of pages6
JournalPediatric transplantation
Volume7
Issue numberSUPPL. 3
DOIs
StatePublished - Mar 24 2003

Keywords

  • Acute leukemia
  • Anti-CD45 antibody
  • Radiolabeled antibodies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Fingerprint Dive into the research topics of 'Use of radiolabeled antibodies in the treatment of childhood acute leukemia'. Together they form a unique fingerprint.

  • Cite this